Mark Scott, chief executive of (), spoke to Proactive London's Andrew Scott following the release of their pre-close trading statement for 2018.
Strong like-for-like growth at its big pharma consultancy division, known as health, offset a slower outcome from brand and marketing operation Signal.
The health division also saw good like-for-like gross profit growth and better-operating margins.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Cello Health PLC named herein, including the promotion by the Company of Cello Health PLC in any Content on the Site, the Company receives from...
FOR OUR FULL DISCLAIMER CLICK HERE